Search

Kadans Science Partner, a European leader in innovation campus development, has joined the Association of Science and Technology Parks of Spain (APTE) as an affiliate member. With operations across

Recently established at the Barcelona Science Park, ALLOX is harnessing cutting-edge technology that merges genetics, artificial intelligence, and energy modeling to explore allosterism — a crucial

53Biologics strengthens its biopharmaceutical capacity in Spain with a new GMP facility in Valladolid, designed in collaboration with Klinea to meet the highest standards and optimize the production

Round led by Jeito Capital, co-led by AXA IM Alts and M Ventures, with strong syndicate support from Ysios Capital and ALSA Ventures

Gate2Brain secures key funding to advance its groundbreaking pediatric brain tumor therapy

The TerminAI project aims to optimize healthcare data management through artificial intelligence, enhancing the efficiency and accuracy of clinical information coding.

Meet our new member MedBioinformatics. We sponke with Patricia Ortega Muñoz, CEO and Medical Director.

Massive data collection accelerated by the digitisation of healthcare, as well as artificial intelligence, is becoming an essential pillar for prevention.

Experts from the sector highlighted at the 18th Annual Conference of the Biomedical Research Technology Platforms the need to promote effective mechanisms for support, funding, and collaboration to

Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases.

Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of

Las biotecnológicas Nuage Therapeutics, Ona Therapeutics y SpliceBio, con sede en el Parque Científico de Barcelona, han sido destacadas en un reciente artículo de la revista 'Nature' como referentes

The company increased its normalized EBITDA by 47%, reaching €13.82 million.